Genetic testing is having a heyday as the process of sequencing genomes becomes cheaper and more ubiquitous. Illumina has capitalized with its testing expertise. It partners with consumer-focused DNA testing services like 23andMe, and with pharma giants like Bristol-Myers Squibb who seek its help with drug development. Last year, the FDA approved Illumina’s companion diagnostic for Amgen’s Vectibix, a drug for metastatic colorectal cancer. In the past 12 months, Illumina has provided a 60% return to shareholders; over the past five years, that figure is 306%.
Life Sciences Tools and Services
Francis A. deSouza
|Revenues ($M) (Past 12 Months)||$3,104|
|Profits ($M) (Past 12 Months)||$648|
|Market Value as of Oct. 10, 2018 ($M)||$44,800|